A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression 
      The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms
      of bipolar I depression and to make sure it is safe in humans.
     Bipolar I Depression :

          -  Bipolar I Disorder, most recent episode depressed

          -  History of 2 or more manic or mixed episodes, at least one of which required
             pharmacologic treatment for manic symptoms

         :

          -  Current manic, hypomanic or mixed episode

          -  Rapid cycling bipolar disorder (4 or more mood episodes in the last year)

          -  Dementia or any other Axis I diagnosis (besides bipolar I) that requires treatment

          -  Alcohol or drug dependence within 6 months; alcohol or drug abuse within 3 months

          -  Positive urine drug test for amphetamines, cocaine metabolites, opiates and/or
             phencyclidine(PCP)

          -  Axis II diagnosis likely to interfere with study compliance

          -  Serious suicidal or homicidal risk

          -  Sensitivity to any of the drug ingredients, including lactose

          -  Women who are pregnant, breast feeding or refuse to use adequate birth control

          -  Current seizure disorder

          -  Current episode of depression is longer than 1 year
      